Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW Jr, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szewczyk JW, Unwalla RJ, Yingling J, Willson TM.
Henke BR, et al. Among authors: johnson mf.
J Med Chem. 1997 Aug 15;40(17):2706-25. doi: 10.1021/jm970265x.
J Med Chem. 1997.
PMID: 9276016